You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Therapy Areas
21 April 2025 - Biopharmaceutical company Gilead Sciences Inc (Nasdaq:GILD) on Monday reported positive topline results from the Phase 3 ASCENT-04/KEYNOTE-D19 trial evaluating Trodelvy (sacituzumab govitecan-hziy) in combination with Keytruda (pembro...
21 April 2025 - Japanese healthcare company Daiichi Sankyo Co Ltd (TYO:4568) and British-Swedish biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (Nasdaq:AZN) on Monday reported positive topline results from the DESTINY-Breast09 phase 3 ...
21 April 2025 - Chinese biopharmaceutical company Akeso Inc (HK:9926) announced on Friday that ebdarokimab, an investigational monoclonal antibody developed by the company, has received marketing approval from China's National Medical Products A...
21 April 2025 - Switzerland-based Ymmunobio AG (YB), which focuses on the development of new cancer therapeutics, announced on Friday that its two-antibody drug conjugate (ADC) assets, YB-800ADC1 and YB-800ADC2, have completed preclinical proof of co...
21 April 2025 - Development-stage biopharmaceutical company SparX Biopharmaceutical Corp announced on Friday that it will present a clinical update on its lead asset, SPX-303, a first-in-class anti-LILRB2/PD-L1 bispecific antibody, during the Trial-i...
17 April 2025 - Dermatology company Sol-Gel Technologies Ltd (NASDAQ:SLGL) revealed on Thursday that it has entered into a product purchase agreement with a subsidiary of Mayne Pharma Group Limited (ASX:MYX) for the sale and exclusive license of the ...
17 April 2025 - Biopharmaceutical company Hoth Therapeutics Inc (NASDAQ:HOTH) announced on Thursday that it has been granted a key patent by the Japan Patent Office, expanding its global intellectual property portfolio in RNA-based precision oncology...